Bossier City criminal lawyers understand exactly what needs to be done to help settle debt.
Our qualified’s Life Sciences and Technologies lawyers are experienced in the complex issues related to biotechnology, genomics, and proteomics, and are well equipped to meet our clients needs in this rapidly expanding technological environment.
Many of these lawyers have extensive experience as general counsel for established Life Sciences companies and high-technology start-ups.
We understand the issues that Life Sciences companies face at the ever-evolving intersection of advanced technology, public policy and business development. We counsel and advise our clients on matters such as disclosure requirements, protecting intellectual property and assets, licensing technology, resolving disputes and managing corporate reputation. Because of our broad-based technology expertise, we can counsel clients addressing sophisticated issues in bio-informatics and related technology merging software and hardware concepts.
We are adept at forming alliances and multi-disciplinary practice groups with entities outside the practice of law, to better arrive at the breadth of services required by companies in this complex area.
Corporate and Securities
Our Corporate attorneys advise clients on the formation, acquisition, financing and development of businesses in the Life Sciences industries. We have represented these companies in both the private and public markets.
We advise Boards of Directors regarding acquisitions, joint ventures and partnerships with an eye to protecting company assets with a proactive intellectual property approach, leading to more integrated acquisitions and development strategies. Our qualified lawyers assist our clients with forming alliances, joint ventures, and outsourcing arrangements in the operations of their businesses. We are familiar with the issues in determining rights to gene sequences and the impact on company decision making in acquisitions and other related alliance formation.
We are especially familiar with Regulation FD and have assisted our clients with a number of disclosure issues that have arisen since the regulation became effective. We also have worked with Life Sciences clients and their independent auditors with respect to the SEC’s interpretations of revenue recognition for collaborations and licenses and the impact of those interpretations on company reporting.
We advise our clients on the many aspects of running genomics and biotech businesses, both in the U.S. and in cross-border circumstances.